Eisai Co ((ESALF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eisai Co., Ltd. is conducting a Phase 1 clinical study titled ‘An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor.’ The study aims to determine the maximum tolerated dose of E7389 liposomal formulation (E7389-LF) and assess its safety, pharmacokinetics, and efficacy in patients with various solid tumors, including breast cancer and small cell lung cancer. This research is significant as it explores new treatment options for patients with limited prior chemotherapy regimens.
The intervention being tested is E7389-LF, a drug administered intravenously. It is designed to target solid tumors, with two dosing schedules being evaluated: one on a tri-weekly basis and another bi-weekly.
The study employs a non-randomized, parallel intervention model with no masking, focusing primarily on treatment. This design allows for a straightforward assessment of the drug’s effects on participants.
The study began on August 18, 2017, with the primary completion date yet to be announced. The latest update was submitted on July 14, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and anticipated results.
This clinical update could influence Eisai Co.’s stock performance and investor sentiment, as successful outcomes may enhance the company’s market position in oncology. Investors should also consider the competitive landscape, as advancements in cancer treatments are highly sought after in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.